Autres langues Gan & Lee Pharmaceuticals.

Actions

603087

CNE100003ZH1

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 07/05/2024			Varia. 5j.	Varia. 1 janv.
51,03 ^CNY	-1,54%		+1,98%	-3,08%

24/04	Gan & Lee Pharmaceuticals. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
24/04	Gan & Lee Pharmaceuticals. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	26/01
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12/12
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	04/12
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	10/11
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	09/11
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12/10/23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18/09/23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18/09/23
Gan & Lee Pharma Advances Trial of New Insulin Product	13/09/23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20/07/23
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20/06/23
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	14/06/23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	24/02/23
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from S&P Global BMI Index	19/12/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Gan & Lee Pharmaceuticals.

Actions

603087

CNE100003ZH1

Autres langues

Filtres